Today: 28 June 2026
Browse Category

NASDAQ:AVTX 6 May 2026

Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics priced a $375 million public offering after reporting positive Phase 2 results for abdakibart in hidradenitis suppurativa. The company will sell 19.73 million shares at $17.75 each and pre-funded warrants for 1.4 million shares. Shares rose 34% to $21.73 by midday. The Phase 2 trial showed HiSCR75 response rates of over 42% for both dosing regimens versus 25.6% for placebo.
6 May 2026
··

Stock Market Today

  • Goldman Sachs Stock Valuation After 50% Yearly Gain: Overvalued or Time to Pause?
    June 28, 2026, 4:07 AM EDT. Goldman Sachs Group's (GS) stock closed at $1,019.61, down 7% in the last week but up 50.6% over the past year. Despite strong multi-year gains-239.1% over three years-the stock shows a recent pullback. Valuation analysis using an Excess Returns model suggests the stock is about 10.4% overvalued, with an intrinsic value estimate of $923.45 per share versus the current price. The company's Price-to-Earnings (P/E) ratio remains a key metric for assessing investor expectations relative to earnings. This price-behavior mix invites investors to carefully weigh valuation models against robust historical returns and shifting market conditions before considering new positions.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 4:07 AM EDT Goldman Sachs Stock Valuation After 50% Yearly Gain: Overvalued or Time to Pause? June 28, 2026, 4:07 AM EDT. Goldman Sachs Group’s (GS) stock closed at $1,019.61, down 7% in the last week but up 50.6% over the past year. Despite strong multi-year gains-239.1% over three years-the stock shows a recent pullback. Valuation analysis using an Excess Returns model suggests the stock is about 10.4% overvalued, with an intrinsic value estimate of $923.45 per share versus the current price. The company’s Price-to-Earnings (P/E) ratio remains
Go toTop